Sign In
Buy A
Agilent Technologies Earnings Calls
| Release date | May 27, 2026 |
| EPS estimate | $1.41 |
| EPS actual | $1.49 |
| EPS Surprise | 5.67% |
| Revenue estimate | 1.799B |
| Revenue actual | 1.835B |
| Revenue Surprise | 2.03% |
| Release date | Feb 25, 2026 |
| EPS estimate | $1.37 |
| EPS actual | $1.36 |
| EPS Surprise | -0.730% |
| Revenue estimate | 1.808B |
| Revenue actual | 1.798B |
| Revenue Surprise | -0.542% |
| Release date | Nov 24, 2025 |
| EPS estimate | $1.58 |
| EPS actual | $1.59 |
| EPS Surprise | 0.359% |
| Revenue estimate | 1.832B |
| Revenue actual | 1.839B |
| Revenue Surprise | 0.365% |
| Release date | Aug 27, 2025 |
| EPS estimate | $1.37 |
| EPS actual | $1.37 |
| Revenue estimate | 1.685B |
| Revenue actual | 1.738B |
| Revenue Surprise | 3.17% |
Last 4 Quarters for Agilent Technologies
Below you can see how A performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 27, 2025 |
| Price on release | $118.69 |
| EPS estimate | $1.37 |
| EPS actual | $1.37 |
| Date | Price |
|---|---|
| Aug 21, 2025 | $117.15 |
| Aug 22, 2025 | $121.63 |
| Aug 25, 2025 | $119.15 |
| Aug 26, 2025 | $118.30 |
| Aug 27, 2025 | $118.69 |
| Aug 28, 2025 | $124.96 |
| Aug 29, 2025 | $125.66 |
| Sep 02, 2025 | $125.21 |
| Sep 03, 2025 | $125.22 |
| 4 days before | 1.31% |
| 4 days after | 5.50% |
| On release day | 5.28% |
| Change in period | 6.89% |
| Release date | Nov 24, 2025 |
| Price on release | $153.60 |
| EPS estimate | $1.58 |
| EPS actual | $1.59 |
| EPS surprise | 0.359% |
| Date | Price |
|---|---|
| Nov 18, 2025 | $143.84 |
| Nov 19, 2025 | $144.40 |
| Nov 20, 2025 | $145.06 |
| Nov 21, 2025 | $151.25 |
| Nov 24, 2025 | $153.60 |
| Nov 25, 2025 | $157.20 |
| Nov 26, 2025 | $154.37 |
| Nov 28, 2025 | $153.50 |
| Dec 01, 2025 | $150.10 |
| 4 days before | 6.79% |
| 4 days after | -2.28% |
| On release day | 2.34% |
| Change in period | 4.35% |
| Release date | Feb 25, 2026 |
| Price on release | $124.72 |
| EPS estimate | $1.37 |
| EPS actual | $1.36 |
| EPS surprise | -0.730% |
| Date | Price |
|---|---|
| Feb 19, 2026 | $126.34 |
| Feb 20, 2026 | $122.90 |
| Feb 23, 2026 | $124.20 |
| Feb 24, 2026 | $124.40 |
| Feb 25, 2026 | $124.72 |
| Feb 26, 2026 | $120.97 |
| Feb 27, 2026 | $121.38 |
| Mar 02, 2026 | $118.17 |
| Mar 03, 2026 | $119.04 |
| 4 days before | -1.28% |
| 4 days after | -4.55% |
| On release day | -3.01% |
| Change in period | -5.78% |
| Release date | May 27, 2026 |
| Price on release | $115.83 |
| EPS estimate | $1.41 |
| EPS actual | $1.49 |
| EPS surprise | 5.67% |
| Date | Price |
|---|---|
| May 20, 2026 | $113.78 |
| May 21, 2026 | $114.79 |
| May 22, 2026 | $114.96 |
| May 26, 2026 | $115.08 |
| May 27, 2026 | $115.83 |
| May 28, 2026 | $135.42 |
| May 29, 2026 | $135.54 |
| Jun 01, 2026 | $135.98 |
| Jun 02, 2026 | $135.05 |
| 4 days before | 1.80% |
| 4 days after | 16.59% |
| On release day | 16.91% |
| Change in period | 18.69% |
Agilent Technologies Earnings Call Transcript Summary of Q2 2026
Agilent delivered a strong Q2 FY2026: revenue of $1.83B, core (organic) growth of 6.3%, operating margin of 26.4% (up 130 bps YoY), and EPS of $1.49 (up 14% YoY). Performance was broad-based across end markets: pharma (+6%), chemical & advanced materials (+8%), diagnostics & clinical (+11%), and particularly forensics (>50%). Instrument sales were strong (high-single-digit, with low-double-digit LC/LC-MS and GC growth) and book-to-bill remained above 1 for the ninth consecutive quarter. Management credited the Ignite operating system for pricing (~200 bps in Q2), supply-chain resilience, productivity, and faster innovation (example: accelerated 9,500 triple quad ICPMS launch). Guidance was raised: FY26 core revenue growth now 4.5%–6.0% (midpoint +30 bps), EPS $6.00–$6.10 (midpoint +$0.08), and operating margin expansion target increased. Cash flow remains healthy (Q2 operating cash flow $277M), net leverage ~0.7x, and capex for FY26 trimmed to ~$450M. Management highlighted continued replacement-cycle momentum, share gains from recent product launches, continued ramp in diagnostics (Omnis), and confidence in Advanced Therapeutics (specialty CDMO) with Train C mechanically complete and revenue pickup expected in H2 and into FY27. Near-term risks noted: China timing/softness in parts of Asia, academic & government softness, and inflationary/geo-political pressures (tariffs and Middle East conflict), but management expects Ignite-driven actions to mitigate these.
